Claimed effect · Mazdutide

Does Mazdutide help with body weight?

A
Grade A — established in humans2 phase 3 RCTs · effect size: large
Short answerEstablished in humans. 2 phase 3 RCTs point the same way: a large effect. GLORY-1, 610 Chinese adults, 48 weeks: −12.0% (4 mg) and −14.8% (6 mg) versus −0.5% placebo; at least 5% loss in 73.5%, 82.8% and 11.5%. GLORY-2, 462 adults, 60 weeks on 9 mg: −18.6% versus −3.0%; 44% lost at least 20%.

What the studies show

GLORY-1, 610 Chinese adults, 48 weeks: −12.0% (4 mg) and −14.8% (6 mg) versus −0.5% placebo; at least 5% loss in 73.5%, 82.8% and 11.5%. GLORY-2, 462 adults, 60 weeks on 9 mg: −18.6% versus −3.0%; 44% lost at least 20%.

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1
    Ji L, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1).N Engl J Med, 2025; DOI 10.1056/NEJMoa2411528610 adults, 48 weeks.
  2. 2
    Innovent. Mazdutide 9 mg achieves up to 20.1% weight loss in Chinese adults with obesity (GLORY-2 topline).Press release, 19 Nov 2025462 adults, 60 weeks; topline, not yet peer-reviewed.

In context

Mazdutide is a once-weekly GLP-1/glucagon dual agonist developed by Innovent with Lilly. In the 610-person GLORY-1 trial, published in the New England Journal of Medicine in May 2025, it produced 14.8% weight loss at 48 weeks on 6 mg against 0.5% on placebo; a 9 mg dose reached 18.6% at 60 weeks in GLORY-2. China's regulator approved it for chronic weight management on 27 June 2025 and later for type 2 diabetes. It is not approved in the US, EU or UK.

Mazdutide is approved in china only. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Mazdutide proven to help with body weight?
Yes, as far as human trials can show it: 2 phase 3 RCTs. LYO grades this outcome A.
What studies are behind the grade?
GLORY-1, 610 Chinese adults, 48 weeks: −12.0% (4 mg) and −14.8% (6 mg) versus −0.5% placebo; at least 5% loss in 73.5%, 82.8% and 11.5%. GLORY-2, 462 adults, 60 weeks on 9 mg: −18.6% versus −3.0%; 44% lost at least 20%.
Is Mazdutide approved for this?
Mazdutide is an approved medicine (Approved in China only); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Mazdutide

Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →